Neurofibromatosis Type 2 C0027832
A genetic disorder causing tumors to grow on nerves, commonly affecting hearing and balance. Management focuses on tumor monitoring, hearing preservation, and surgical intervention when necessary.
Key facts at a glance
- ICD-10
- Q85.02
- ICD-11
- LA00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Severe headache
Bilateral sensorineural hearing loss
(neurologic)Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Tinnitus
(neurologic)Posterior subcapsular cataracts
(ophthalmic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Tumor Surveillance Protocol
Regular MRI imaging and clinical monitoring of vestibular schwannomas, meningiomas, and other associated tumors to detect growth and guide intervention timing. Typically includes annual audiometric testing.
Additional treatment options
Vestibular Schwannoma Resection
Surgical removal of growing vestibular schwannomas, with the goal of tumor control while preserving facial nerve function and hearing when possible. Approach tailored to tumor size and patient factors.
surgicalAuditory Brainstem Implant
Surgical placement of an auditory brainstem implant to provide hearing sensation in patients who have lost hearing due to tumor treatment or progression. Requires extensive rehabilitation for effective use.
procedureTargeted Molecular Therapy
Use of targeted therapies such as bevacizumab to reduce tumor size and stabilize disease in selected patients with progressive vestibular schwannomas. Treatment requires careful monitoring for response and side effects.
medicationPsychological Support Services
Mental health support addressing anxiety, depression, and adjustment challenges associated with progressive neurological disease, hearing loss, and treatment decisions. Includes counseling and support groups.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Neurofibromatosis Type 2 C0027832?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Neurofibromatosis Type 2 C0027832. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy